Stock NDRA ENDRA LIFE SCIENCES INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials ENDRA Life Sciences Inc.

Equities

NDRA

US29273B3024

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 04:30:00 2024-04-26 pm EDT 		5-day change 1st Jan Change
0.2525 USD +4.12% Intraday chart for ENDRA Life Sciences Inc. +2.23% -88.09%
Mar. 28 Transcript : ENDRA Life Sciences Inc., Q4 2023 Earnings Call, Mar 28, 2024
Mar. 28 ENDRA Life Sciences Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Capitalization 1 12.63 25.23 29.17 12.86 17.92 2.787
Enterprise Value (EV) 1 12.63 25.23 29.17 12.86 17.92 2.787
P/E ratio -0.72 x -1.19 x -2.47 x -0.89 x -1.34 x -0.18 x
Yield - - - - - -
Capitalization / Revenue - - - - - 2.79 x
EV / Revenue - - - - - 2.79 x
EV / EBITDA -1,173,307 x - - - - -
EV / FCF - - - - - -
FCF Yield - - - - - -
Price to Book - - 2.73 x 1.79 x 2.38 x -0.25 x
Nbr of stocks (in thousands) 376 1,682 2,108 3,159 8,455 11,036
Reference price 2 33.60 15.00 13.84 4.070 2.120 0.2525
Announcement Date 3/26/20 3/25/21 3/30/22 3/14/23 3/28/24 -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net sales 1 - - - - - 1
EBITDA -10.76 - - - - -
EBIT 1 -10.84 -11.5 -11.5 -13.16 -10.52 -12.3
Operating Margin - - - - - -1,230%
Earnings before Tax (EBT) 1 -13.31 -11.73 -11.23 -13.18 -10.06 -12.3
Net income 1 -17.53 -12.12 -11.35 -13.18 -10.06 -12.3
Net margin - - - - - -1,230%
EPS 2 -46.80 -12.60 -5.600 -4.560 -1.580 -1.410
Free Cash Flow - - - - - -
FCF margin - - - - - -
FCF Conversion (EBITDA) - - - - - -
FCF Conversion (Net income) - - - - - -
Dividend per Share - - - - - -
Announcement Date 3/26/20 3/25/21 3/30/22 3/14/23 3/28/24 -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2023 Q4 2024 Q1 2024 Q2 2024 Q3 2024 Q4
Net sales 1 - - - - - - - - - - 0.1 0.1 0.3 0.5
EBITDA - - - - - - - - - - - - - -
EBIT 1 -2.651 -3.072 -2.855 -3.572 -3.417 -3.313 -2.939 -2.995 -3.129 -1.5 -3.2 -3.2 -3.1 -3
Operating Margin - - - - - - - - - - -3,200% -3,200% -1,033.33% -600%
Earnings before Tax (EBT) 1 -2.658 -3.105 -2.858 -3.591 -3.44 -3.29 -2.943 -2.557 -3.101 -1.5 -3.2 -3.2 -3.1 -3
Net income 1 -2.658 -3.105 -2.858 -3.591 -3.44 -3.29 -2.943 -2.557 -3.101 -1.5 -3.2 -3.2 -3.1 -3
Net margin - - - - - - - - - - -3,200% -3,200% -1,033.33% -600%
EPS 2 -1.200 -1.400 -1.400 -1.200 -1.000 -0.9600 -0.9300 -0.4300 -0.4000 -0.1700 -0.3700 -0.3600 -0.3500 -0.3300
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 11/15/21 3/30/22 5/12/22 8/15/22 11/14/22 3/14/23 5/15/23 8/14/23 11/14/23 3/28/24 - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024
Net Debt - - - - - -
Net Cash position - - - - - -
Leverage (Debt/EBITDA) - - - - - -
Free Cash Flow - - - - - -
ROE (net income / shareholders' equity) - - - - - -
ROA (Net income/ Total Assets) - - - - - -
Assets 1 - - - - - -
Book Value Per Share 2 - - 5.070 2.270 0.8900 -1.000
Cash Flow per Share - - - - - -
Capex 1 0.04 - 0.05 0.2 0.03 0.1
Capex / Sales - - - - - 10%
Announcement Date 3/26/20 3/25/21 3/30/22 3/14/23 3/28/24 -
1USD in Million2USD
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.2525 USD
Average target price
11 USD
Spread / Average Target
+4,256.44%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

1st Jan change Capi.
ENDRA LIFE SCIENCES INC. Stock ENDRA Life Sciences Inc.
-88.09% 2.79M
IQVIA HOLDINGS INC. Stock Iqvia Holdings Inc.
+1.51% 42.75B
LONZA GROUP AG Stock Lonza Group AG
+48.32% 41.61B
MODERNA, INC. Stock Moderna, Inc.
+8.57% 41.34B
CELLTRION, INC. Stock Celltrion, Inc.
-12.36% 26.59B
ICON PUBLIC LIMITED COMPANY Stock ICON Public Limited Company
+8.92% 25.49B
ALNYLAM PHARMACEUTICALS, INC. Stock Alnylam Pharmaceuticals, Inc.
-25.13% 18.12B
MEDPACE HOLDINGS, INC. Stock Medpace Holdings, Inc.
+29.17% 12.24B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC. Stock Charles River Laboratories International, Inc.
-3.12% 11.76B
UNITED THERAPEUTICS CORPORATION Stock United Therapeutics Corporation
+6.35% 11B
Other Biotechnology & Medical Research
  1. Stock Market
  2. Equities
  3. NDRA Stock
  4. Financials ENDRA Life Sciences Inc.